We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Supernus Pharmaceuticals Inc | NASDAQ:SUPN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.72 | -2.50% | 28.05 | 26.00 | 42.01 | 28.77 | 27.63 | 28.74 | 706,784 | 01:00:00 |
From May 2023 to May 2024
By Stephen Nakrosis
Supernus Pharmaceuticals resubmitted a new drug application to the Food and Drug Administration for its apomorphine infusion device to treat patients with Parkinson's disease.
The SPN-830 apomorphine infusion device is designed for the continuous treatment of motor fluctuations in Parkinson's disease.
In October 2022, Supernus said it received a complete response letter from the FDA indicating the company's NDA wouldn't be approved in its then-current form. At the time, Supernus said the FDA was seeking additional information and analysis, but didn't request additional efficacy or clinical studies.
The company also said "the FDA mentioned at the time that approval of the NDA required inspections that could not be completed in a timely manner due to Covid-19 travel restrictions."
Supernus said it believes it addressed the FDA's questions related to the complete response letter and will continue to work with the agency as it reviews the SPN-830 NDA.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 09, 2023 17:30 ET (21:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Supernus Pharmaceuticals Chart |
1 Month Supernus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
